



Confounders Effecting Quality of Life of COPD Patients in European Union: A Systematic Review

Sara Shahid ^a, Zuha Tariq ⁺⁺⁺, Obeda Asghar ⁺⁺⁺,
Arooj Majeed ⁺⁺⁺, Umair Amjad ⁺⁺⁺, Wasiq Ali ⁺⁺⁺,
Ahmad Sarfaraz ⁺⁺⁺, Muhammad Ahmed Saeed ⁺⁺⁺,
M.Sohaib Sultan Sabri ⁺⁺⁺, Mohammad Abdullah ⁺⁺⁺,
Azwa Zaheer ⁺⁺⁺, Muhammad Aamir ⁺⁺⁺, Talha Rehman ⁺⁺⁺
Asfa Iqbal ⁺⁺⁺ and Muhammad Zahid Iqbal ^{a*}

^a Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Lahore University of Biological & Applied Sciences, Lahore, Pakistan.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2024/v36i27501

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/114123>

Systematic Review Article

Received: 02/01/2024

Accepted: 07/03/2024

Published: 12/03/2024

ABSTRACT

Introduction: Chronic Obstructive Pulmonary Disease (COPD) is a respiratory disease characterized by restriction in expiratory airflow. It is among one of the major causes of illness and death globally. COPD causes severe negative effects on physical and mental health. It has a drastic effect upon the health-related quality of life of patients. Numerous factors contribute towards morbidity of COPD that include smoking, obesity, air pollutants and comorbid conditions (cardiovascular diseases, diabetes mellitus, arterial hypertension, infections).

⁺⁺ Research Student;

^{*}Corresponding author: E-mail: drmmziqbal@gmail.com;

Aims and Objectives: The current systematic review was conducted with the aim to determine the health-related quality of life of COPD patients as well as the confounders of quality of life.

Methodology: A systematic review was conducted of 22 studies. The electronic databases used to search the articles were Pubmed, Scopus, Science Direct, ProQuest, Web of Science. Total 1880 studies were found, out of which only 22 studies met the inclusion criteria. All the studies included are within 2017-2022. Patients met inclusion criteria have less than 70% FEV1/FVC ratio and diagnosis of patients was according to the GOLD staging system. Majority study design were observational, some were cross sectional, experimental and randomized clinical trials. Mean age of patients observed was 40-85 years. To assess the quality of life of COPD patient specific questionnaires has been used like SGRQ, CAT, CCQ, EQ-5D-5L.

Results: Included studies shows that the quality of life of COPD is compromised physically as well as mentally. It is due to less physical activities, smoking habits, psychological issues, comorbidities like diabetes mellitus, cardiovascular diseases, arterial hypertension.

Conclusion: All the studies concluded that COPD patients diagnosed on basis of GOLD criteria and their quality of life is assessed via disease specific questionnaires that majorly includes SGRQ, CAT, CCQ, EQ-5D-5L. And it shows that quality of life of COPD decreases overall. However, the major confounders of reduced quality of life in COPD patients were: Smoking, raised BMI, high cholesterol, Depression/ anxiety, traffic related air pollutants, malnutrition and co-morbid conditions such as hypertension, asthma, anemia and diabetes mellitus.

Keywords: Quality of life; COPD patients in European union, assessment of HRQoL of COPD patients; CAT; SGRQ; acute exacerbations in COPD patients.

ABBREVIATIONS

<i>BMI</i>	: <i>Body Mass Index,</i>
<i>COPD</i>	: <i>Chronic Obstructive Pulmonary Disease,</i>
<i>CVD</i>	: <i>Cardiovascular Diseases,</i>
<i>CAT</i>	: <i>COPD Assessment Test,</i>
<i>CRQ</i>	: <i>Chronic Respiratory Questionnaire,</i>
<i>CCQ</i>	: <i>Clinical COPD Questionnaires,</i>
<i>FEV</i>	: <i>Forced Expiratory Volume,</i>
<i>FVC</i>	: <i>Forced Vital Capacity,</i>
<i>GOLD</i>	: <i>Global Initiative for Chronic Obstructive Lung Disease,</i>
<i>HRQoL</i>	: <i>Health Related Quality of Life,</i>
<i>SGRQ</i>	: <i>St George's Respiratory Questionnaire,</i>
<i>WHOQOL</i>	: <i>World Health Organization Quality of Life Questionnaire,</i>
<i>RCT</i>	: <i>Randomized Controlled Trial.</i>

1. INTRODUCTION

“Chronic obstructive pulmonary disease (COPD) is a respiratory disease with obstruction in the respiratory airflow. Numerous anatomical abnormalities including fibrosis could be the reason of this obstruction in air flow. Airflow restriction can also be occasionally caused by bronchi secretions, edema and air ways inflammation” [1].

“One of the main causes of morbidity and mortality globally is chronic obstructive pulmonary disease (COPD). Dyspnea, airflow

restriction, skeletal muscle dysfunction and comorbidities contribute to the functional decline and obstruction in airways, that COPD patients experience on daily basis” [2]. The stated prevalence of COPD varies according to the geographic area; in Europe, it is about 4% [3].

“Patients with this chronic illness experience severe negative effects on their physical and mental health, as it negatively affects systems and organs other than the lungs. This can result in pneumonia, pulmonary hypertension, and cardiovascular disease (CVD)” [3].

“The World Health Organization estimates that 210 million people worldwide suffer from COPD, and that the disease claimed 3 million lives in 2005. A substantial decline in quality of life (QoL) and high rates of morbidity and mortality are linked to COPD, particularly but not only in the later stages of the illness. According to the most recent estimates provided by the Global Burden of Disease Study, COPD ranked third globally in 2010 for causes of death” [4]. “Between 1994 and 2010, 2,348,184 fatalities were ascribed to COPD in the European Union. The prevalence of COPD in Europe has been reported to range between 4% and 10%. Forced expiratory volume in one second (FEV1) is used to determine the severity of COPD. Nevertheless, there is little correlation between FEV1 and the disease's clinical signs. For a more thorough evaluation of the severity of the disease, and standardized measurement of patient-related outcomes (such

as health status) has been suggested. Patients with COPD have been found to have high rates of diabetes, cardiovascular illness, and mental disorders (such as depression and anxiety)" [4].

"When it comes to inflammatory cells, mediators, inflammatory effects, and therapy response, the inflammatory process in COPD differs greatly from that in asthma" [5]. "COPD is of late onset, slowly progressive symptoms, poor response to inhaled therapy, and typically associated with long-term smoking, asthma typically has an early onset with intermittent symptoms, a good response to inhaled therapy, and is frequently associated with other allergy diseases" [6,7].

Whereas COPD is caused by a Noxious Agent (primarily cigarette smoking), asthma is caused by a Sensitive Agent. While airflow restriction in asthma is fully reversible, it is not in COPD cases. Asthma is characterized by variable wheezing, while COPD is characterized by persistent symptoms. In asthma, bronchial hyperreactivity (BHR) is expressive, whereas in COPD, it is minimal. In cases of asthma, bronchodilators and corticosteroids are beneficial; in cases of COPD, they are essentially ineffective [6].

It is acknowledged that one of the most prevalent and significant symptom of COPD is fatigue. [8] One of COPD's hallmark symptoms, dyspnea, can be a powerful inducer of anxiety. In the multivariable analysis, COPD was linked to an increased risk of anxiety. Anxiety was linked to worse health outcomes in COPD patients and make them avoid any physical activities [9,10]. Research has indicated that malnourishment or low body weight is prevalent amongst people with COPD; it affects roughly 10-15% of patients with mild-to-moderate disease and 50% of patients with chronic respiratory failure and advanced stages of the disease [11,12]. Patients with COPD complained of a variety of symptoms and experienced a lower standard of living [13].

Reduced dyspnea, increased exercise tolerance, enhanced quality of life, and averting future risks are the objectives of care for COPD patients. Drugs with anti-inflammatory qualities and both short- and long- acting bronchodilators are included in pharmacological approaches [14]. The bronchodilators may be used as needed or as a long-term maintenance treatment, depending on the severity of the illness. Inhaled corticosteroids are added to the treatment regimen when the disease reaches a severe stage. Treating COPD at any stage of the

disease is possible even though it cannot be cured. Along with recommendations for patient treatment, the guidelines that offer information to aid in the diagnosis of COPD also include risk-reduction tactics, lifestyle modifications, and medication recommendations. Supplemental oxygen can help patients with severe COPD who may also have hypoxemia and/or hypercapnia. This treatment can also increase the patients' ability to exercise. Participation in pulmonary rehabilitation, which is advised for all patients with COPD, is a beneficial adjunct to medication [15].

"Previous studies related to quality of life in COPD patients tells the following: Loanna, et al described that chronic obstructive pulmonary disease (COPD) is a prevalent disease in the general population and a considerable burden for patients with the disease. This burden differs between patient groups. Some patients can live their lives almost untouched by the disease, while others are almost completely handicapped. One way to indicate the burden of the disease to patients is assessment of health-related quality of life (HRQoL) and health status. Quality of life (QoL) in general refers to the patient's ability to enjoy normal life activities" [16]. "Margarethe reported that health-related quality of life (HRQL) of COPD patients typically declines: The overall severity of COPD is influenced by symptoms such as cough, dyspnea, and sputum production, as well as by acute exacerbations of the disease and comorbidities that are common in COPD patients" [17]. Regis, et Al described that patients with COPD have been found to have high rates of diabetes, cardiovascular illness, and mental disorders (such as depression and anxiety). According to reports, these comorbidities greatly raised the probability of treatment expenditures as well as death and hospitalizations for COPD patients. It has been observed that several respiratory characteristics, such as the degree of airflow restriction, dyspnea, and recurrent exacerbations, are independently linked to a lower quality of life (HRQoL). There is limited information available regarding the effects of other comorbidities, such as diabetes and cardiovascular disorders, on HRQoL. However, recent research have further revealed that COPD participants with anxiety and/or depression had decreased HRQoL [18].

The questionnaires used to assess quality of life in COPD patients are as following. The Chronic Respiratory Questionnaire (CRQ) [19], Severe Respiratory Insufficiency (SRI) instrument was studied in one study in oxygen dependent COPD

patients [20], COPD Assessment Test (CAT) was studied in eight studies in mainly pulmonary rehabilitation patients and in one study in primary care patients, St. George Respiratory Questionnaire (SGRQ) was studied in 26 papers in different settings (community, hospital, and pulmonary rehabilitation), Shorter form SF-12 (SF-12) was studied in one study in exacerbation patients [21], HRQOL was assessed using the EQ-5D-3L, which is a validated instrument, Clinical COPD Questionnaire (CCQ) was studied in eight studies. Utility measure EuroQol EQ5D was studied in five studies in hospital [22].

2. METHODOLOGY

2.1 Study Design

Study protocols were according to the PRISMA flow diagram guidelines. This study is a literature review of about 22 studies from the European Union. Study search is done by the electronic databases along with the manual search on Google scholar. The research is restricted to the English language. The study designs of the studies involved were cross sectional, cohort, observational, longitudinal, randomized, nonrandomized controlled and controlled perspective study.

In identification step, all the data collected is searched from different databases and registers like Pubmed, Scopus, Science Direct, ProQuest, Web of Science. Almost 1880 studies were searched from databases like 648 from Pubmed, 578 from Scopus, 340 from science direct, from ProQuest we got 200 and from Web of Science we found 114 studies. Out of 1880, after screening 750 studies were removed because of duplicate record. 25 studies were record renounced and were also removed from the record. 1105 studies left in record. After further screening 945 studies were again excluded from the records. 160 studies sought for retrieval out of which 43 studies did not have full text available and on this basis they were excluded from record. Studies remain in assessment for eligibility are 117 at this point. They are further filtered out. 40 studies got excluded because they didn't belong to European Union. 25 studies screened out because they had no clear impact on quality of life in COPD patients. Further on 20 articles were not published in journals and 10 studies didn't explain any questionnaire for the quality of life of COPD patients. At last stage only 22 studies were included that met the criterias for review.

2.1.1 Inclusion criteria

22 studies met the inclusion criteria. Criteria is as follows:

- 1- All the patients suffering from COPD
- 2- Population to be taken is from European Union
- 3- Assessment of HRQoL of COPD patient is done in study
- 4- Studies that used specific questionnaires for assessing QoL
- 5- Age of patients is above 55 years
- 6- Studies were published in English language
- 7- The studies were published in peer reviewed journals
- 8- Measurement of FEV1/FVC value is done in studies
- 9- Patients classified according to GOLD staging system

2.1.2 Exclusion criteria

Exclusion criteria were as follows:

- 1- Patients having asthma are excluded
- 2- Articles that were related to oxygen therapy
- 3- Questionnaire that doesn't measure QoL of COPD patients were excluded
- 4- Study other than in English language was excluded
- 5- Studies other than from European Union were excluded

2.1.3 Data extraction

The data which was extricated from research studies included: study titles, authors, study year, university country, study design, mean age/gender, inclusion criteria, study population, questionnaire, result of QoL, factors that are causing reduced QoL.

2.1.4 Data synthesis and analysis

The effect of Chronic obstructive pulmonary disease on the patients' health has been investigated from all the studies. And how COPD reduces the quality of life of COPD patients and factors that are involved in reducing HRQoL has been assessed. Decrease in physical activities and exercise has been observed. Hypoxemia and dyspnea is also seen in COPD patients.

3. RESULTS

The topic of our study is “Systematic review of quality of life of COPD patients in European Union”. The studies included in this review were 22 in number. All the studies showed the assessment of quality of life in COPD patient. Shows all the factors and activities that reduces the quality of life. For the assessment of HRQoL, there are some specific and standard questionnaires i.e. SGRQ, CAT, EQ-5D-3L etc. Data extracted includes study year, author, study design, inclusion criteria, sample population, age, gender, factors affecting QoL of patients.

Study Year: Total 22 studies were conducted from 2017-2022. Out of which two studies were from year 2017, three studies from 2018, three studies from 2019, eight studies from 2020, two studies from 2021, and four studies from 2022 were taken.

Country: All the studies taken were from countries included in European Union. Out of 22 studies, five studies were collected from Spain, three studies from Denmark, four studies from Germany, one from Austria and one from Netherlands. In a similar manner, one study was picked from each of these following: Bulgaria, Marbug, Hungary, the Solvak Republic, Sweden, and Poland.

Study Design: In these 22 studies, fourteen studies belong to observational study design, eight studies from cross sectional study, one study from cohort clinical trial, four studies from observational longitudinal study, one from controlled prospective study, seven studies from experimental study design, six studies from randomized clinical trial, one from non-randomized clinical trial, and last from descriptive study (survey data) has been included.

Mean Age/Gender: Both male and female subjects were participated in our study. Mean age of the subjects was between the range of 40-85.

Ratio of males were comparatively greater than females.

Inclusion Criteria: Patients with age >40 years who are diagnosed with GOLD criteria were selected in our study. FEV1/FVC ratio less than 70% of patients were included. Patients who received a diagnosis based on ATS/ERS were also included. Patients with a history of smoking 10–20 packs per day were chosen. The study

included retired individuals with an HRQOL of 41.7% and married patients with an HRQOL of 58.3%. Furthermore, the study included computer-illiterate people with more than two hospitalizations and patients with respiratory failure.

Study Population: Study population shows the sample size of patients involved in studies and surveys. All the patients in studies participated gave written informed consent. The evaluation of patients has been done over the years from 1-5 year in different studies. And majority of patients were taken from hospital settings.

Maximum sample size includes 11,577 patients under study. One of the study based on real world analysis examined 3016 COPD patients over one year. Another study shows 543 patients in sample size examined over 5 years and at the end of period only 324 left.

Mostly sample includes geriatrics. Minimum sample size included was of 94 patients and its study period was 12 months, at the end of study 53 patients left.

Each Sample size further divided into two or three groups of control group, cohort group, physical therapy group, self management group etc.

Questionnaire: Different questionnaire are used for the assessment of health related quality of life in COPD patients. Out of 22 studies, 7 studies used St. George's Respiratory questionnaire (SGRQ). In these 7 studies, 5 studies used SGRQ alone and one study used it along with other questionnaires including EQ-5D-5L and Clinical COPD questionnaires' (CCQ). One study used SGRQ, EQ-5D-5L, CCQ and also CAT (COPD assessment test) to assess quality of life.

Further on, 8 studies used the questionnaire CAT. Out of 8, 4 articles used CAT questionnaire along with combination of different other questionnaires for the assessment of quality of life. These includes EORTC30, EQ-5D-5L, CCQ, mMRC, 15D QoL.

15D questionnaire is used in one study. Short form-12 and short form-36 health survey questionnaire are being used in the study of Germany and Sovak Republic respectively.

Clinical COPD questionnaire has been used in 3 of the studies in combination with different questionnaires.

In one study Chronic Respiratory Questionnaire (CRQ) is used. Two studies holds EQ-5D-3L and SRI questionnaire respectively.

Health Organization (WHOQOL-100) questionnaire for the assessment of quality of life of COPD patients.

One article from Ukarian and Poland, did not use particular HRQoL questionnaire for COPD patients. They used Ukrainian version of World

Total 3 studies used EuroQoL Five-Dimensional Five-Level Questionnaire (EQ-5D-5L) with combination with other questionnaires.




Fig. 1. Prisma flow diagram for systematic review

*Consider, if feasible to do so, reporting the number of records identified from each database or register searched (rather than the total number across all databases/registers)

**If automation tools were used, indicate how many records were excluded by a human and how many were excluded by automation tools

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71 For more information, visit: <http://www.prisma-statement.org/>

Table 1. Quality assessment of included studies using AXIS tool

AXIX tool items	Study 1 [23]	Study 2 [24]	Study 3 [25]	Study 4 [26]	Study 5 (Szentes et al., 2020)	Study 6 [27]	Study 7 [28]	Study 8 [29]	Study 9 [30]	Study 10 [31]	Study 11 [32]	Study 12 [33]	Study 13 [34]	Study 14 [35]	Study 15 [36]	Study 16 [37]	Study 17 [38]	Study 18 [39]	Study 19 [40]	Study 20 [41]	Study 21 [42]	Study 22 [43]
Were the aims/objectives of the study clear?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the study design appropriate for the stated aim(s)?	Yes	No	Yes	Yes	Yes	Yes	No	Yes	No	No	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes
Was the sample size justified?	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes
Was the target/reference population clearly defined?	No	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	No	Yes	No	Yes	Yes	No	No	Yes	Yes	Yes	Yes
Was the sample frame taken from an appropriate population base so that it closely represented the target/reference population under investigation?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the selection process likely to select subjects/participants that were representative of the target/reference population under investigation?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were measures undertaken to address and categorise non-responders?	No	No	No	No	No	Yes	Yes	Yes	No	No	Yes	No	Yes	No	Yes	No	No	No	Yes	Yes	Yes	Yes
Were the risk factor and outcome variables measured appropriate to the aims of the study?	Yes	No	No	Yes	No	Yes	No	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	Yes	No	Yes	Yes	Yes	Yes
Were the risk factor and outcome variables measured correctly using instruments/measurements that had been trialled, piloted or published previously?	Yes	Yes	No	Yes	Yes	Yes	No	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Is it clear what was used to determine statistical significance and/or precision estimates? (e.g. p-values, confidence intervals)	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were the methods (including statistical methods) sufficiently described to enable them to be repeated?	Yes	No	No	Yes	Yes	Yes	No	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	yes	Yes	Yes	Yes	Yes	Yes

AXIX tool items	Study 1 [23]	Study 2 [24]	Study 3 [25]	Study 4 [26]	Study 5 (Szentes et al., 2020)	Study 6 [27]	Study 7 [28]	Study 8 [29]	Study 9 [30]	Study 10 [31]	Study 11 [32]	Study 12 [33]	Study 13 [34]	Study 14 [35]	Study 15 [36]	Study 16 [37]	Study 17 [38]	Study 18 [39]	Study 19 [40]	Study 20 [41]	Study 21 [42]	Study 22 [43]
Were the basic data adequately described?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Does the response rate raise concerns about non-response bias?	No	No	No	No	No	Yes	No	Yes	No	No	Yes	No	Yes	No	No	No	No	No	Yes	Yes	Yes	Yes
If appropriate, was information about non-responders described?	No	No	No	No	No	Yes	Yes	Yes	No	No	Yes	No	Yes	No	No	No	No	No	Yes	Yes	Yes	Yes
Were the results internally consistent?	Yes	No	No	Yes	Yes	Yes	No	Yes	No	No	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	yes	Yes	Yes	Yes
Were the results presented for all the analyses described in the methods?	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were the authors' discussions and conclusions justified by the results?	Yes	yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were the limitations of the study discussed?	Yes	No	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	No	Yes
Were there any funding sources or conflicts of interest that may affect the authors' interpretation of the results?	No	No	No	No	No	No	No	No	No	Yes	No	No	No	No	No	yes	No	No	Yes	No	No	Yes
Was ethical approval or consent of participants attained?	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	No	Yes	No	Yes	No	Yes	No	Yes	Yes

Table-2. Study characteristics of the included 22 studies

Sr. No.	Study	Study year	University / Country	Study design	Mean age / Gender	Inclusion Criteria	Study population	Questionnaire used	QoL	QoL-Confounders
1.	Quality of Life and Limitations in Daily Life of Stable COPD Outpatients [23]	2020	Kepler University Hospital, Department of Pulmonology, Austria	Cross-sectional study design	62.8% men; mean age 66.2 ± 0.3 (SE) years	Inclusion: age ≥40 years, a physician's diagnosis of COPD according to GOLD recommendations.	850 patients; mean FEV1%pred. 51.5 ± 0.6 (SE)) were analysed.	St. George's Respiratory Questionnaire for COPD patients	Half of the patients (50.3%) reported not being able to do any sports and 78.7% stated that their respiratory symptoms did not allow them doing anything they would like to do.	Diabetes mellitus, Arterial hypertension, Cardiac disease, Smoking status
2.	Two-year mortality following a severe COPD exacerbation in Bulgarian patients [24]	2022	Department of Occupational Diseases, Department of Pulmonary Diseases, Central Clinical Laboratory, Medical University Sofia Bulgaria	observational	*Mean age, years 65.1 (± 9.9) years * Male / Female= 108 (71.1%) / 44 (28.9%)	included patients had FEV1/FVC ratio < 0.70 following administration of a bronchodilator.	152 consecutive COPD patients hospitalized for COPD exacerbation who gave written informed consent	CAT and mMRC questionnaire	the presence of severe exacerbation, reduced quality of life, low BMI—increased mortality	Low HDL, Smoking
3.	Effect of tele- health care on quality of life in patients with severe COPD [25]	2018	Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark	Randomized clinical trial	68-70 years old females	*Post-bronchodilator forced expiratory volume in 1 second [FEV1]/forced vital capacity ,0.7. *Post-bronchodilator FEV1,60% of predicted value.	281 (51.2%) patients gave written informed consent to study participation	15D Qol questionnaire, CAT	A small improvement in the QoL	degree of symptoms and physical functioning
4.	Factors associated with generic health-related quality of life (HRQOL) in patients with (COPD) [26]	2017	University of Regensburg, Regensburg, Germany	cross-sectional study, prospective patient cohort study	65 years old (SD =8.85) 2/3 are male sex	Patients were recruited from primary care and specialist practices as well as from in- and outpatients from hospital settings	206 COPD patients (60.7% male; mean age: 65.3 years)	Short-Form 12 (SF-12) Health Survey Questionnaire	HRQoL is reduced by psychiatric activities	Depression, anxiety
5.	Measuring quality of life in COPD patients: comparing disease-specific supplements to the EQ-5D-5L (Szentes et al., 2020)	2019	Ludwig-Maximilian's-University Munich, Germany	cross-sectional study	65± 5years	Analyzed patient-level information from DMP documentation and health insurance claims data. No more inclusion criteria is mentioned in study	1,350 participants	EuroQoL Five-Dimensional Five- Level Questionnaire (EQ-5D-5L), CAT, CCQ, SGRQ	Reduced QoL is seen in patients	--
6.	The relationship between BMI and health-related quality	2020	Institute of Health Economics and Health Care	Survey data (real-world evidence)	Age 65 ±5years, Female: 4,751 (41.0%), Male: 6,826 (59.0%)	Patients who participated in the COPD disease	11,577 patients	--	severe COPD might improve following weight	Obesity

Sr. No.	Study	Study year	University / Country	Study design	Mean age / Gender	Inclusion Criteria	Study population	Questionnaire used	QoL	QoL-Confounders
	of life in COPD [27]		Management, Germany			management program (DMP) in the respective year were included in this evaluation			reduction	
7.	Optimizing COPD treatment in patients with lung or head and neck cancer does not improve quality of life – a randomized, pilot, clinical trial [28]	2020	Copenhagen University Denmark	Experimental (randomized control trial) RCT	Age: 65±5 Females patients	Patients with an FEV1/FVC ratio <0.70, no significant beta-2- reversibility and no actual or pre- vious doctor- diagnosed asthma were eligible	114 patients	CAT and EORTC30 questionnaire	In this population of severely ill cancer patients, we did not find that this intervention, focusing on inhaled COPD medication, for the management of COPD had any convincing positive impact on the patients' perceived quality of life compared with usual care	Lung cancer, head and neck cancer
8.	Impact of Lung Function and Exacerbations on Health-Related Quality of Life in COPD Patients Within One Year: Real-World Claims Data [29]	2021	1-Helmholtz Zentrum München, Neuherberg, Germany 2-IBE, Ludwig-Maximilians University Munich, Germany 3-Philipps-University Marburg, Germany	Observational, longitudinal study	59.8% were male, mean age was 68.9 years,	--	3016 COPD patients	EQ-5D-5L, (St. George's Respiratory Questionnaire (SGRQ), Clinical COPD Questionnaire (CCQ))	FEV1 decrease was associated with a significant but not minimal important difference (MID) deterioration in disease-specific HRQoL (mean change [95% CI]: CAT +0.74 [0.15 to 1.33])	Smoking Obesity
9.	Implementation of an integrated care model for frequent-exacerbator COPD Patients [30]	2020	Son Espases University Hospital – IDISBA Spain	Controlled prospective study	Age: 75±5years Male/Female = for standard care group 102 (77.3)/30 (22.7) And for ICM group 101 (71.6)/40 (28.4)	COPD patients diagnosed according to gold criteria with history of >2 AECOPD Required hospitalization and fulfilled inclusion criteria with no exclusion criteria for ICM	141 patients	CAT	Decreases ER and hospital admission and improves health status, but not mortality	Age, Pseudomonas aeruginosa are factors that causes severity of disease.
10.	Role of physical environment in health-related quality of life in patients with COPD [31]	2022	Pompeu Fabra University Barcelona, Spain	Cross sectional study (Randomized controlled trial)	Mean age of 69years 85% of males.	Patients approaching any of 33 primary care centers and five tertiary hospitals of	Sample size was 407 geriatrics patients	CAT, CCQ	Reduced QoL in patients	Traffic related air pollutants, residential distances to blue green spaces

Sr. No.	Study	Study year	University / Country	Study design	Mean age / Gender	Inclusion Criteria	Study population	Questionnaire used	QoL	QoL-Confounders
						five seaside and diagnosed with COPD according to ATS/ERS were recruited				
11.	Patient education during hospital admission due to exacerbation of COPD [32]	2018	University Jaume I, Castellon de la Plana, Spain	Controlled and randomized experimental study	Age: Mean±(SD) = 73.0 (9.4) Males: 94 (81.0) Females: 22 (19.0)	Patients diagnose with COD based on a history of smoking of 20 packs per year along with barely reversible air flow obstruction	Sample size was 446	SGRQ	Mean hrql score upon admission was 48.3+-20.0 Decreased in the IG on average by 6.83 points. CG barely shows changes in scores with avg reduction of 0.26 points Average drop of 15.76 in absolute change and an average drop of 23.99% in relative change	Smoking, malnutrition
12.	Effects of omega-3 supplementation on quality of life, nutritional status, inflammatory parameters, lipid profile, exercise tolerance and inhaled medications in COPD [33]	2022	Semmelweis University, Faculty of Medicine, Budapest, Hungary	CROSS SECTIONAL	Age: Omega3 consumer: 57.5-72.5 Omega3 non-consumer: 61-73 Man: Omega consumer=10 (52.63%) Omega3 non-consumer=180 (47.24%) Woman: Omega consumer= 9 (47.37%) Omega3 non-consumer= 201 (52.76)	Inclusion criteria were: age ≥40 years and diagnosis of COPD [post-bronchodilation of forced expiratory volume in one second/forced vital capacity (FEV1/FVC) <70%].	400 patients	CAT	We observed better quality of life (CAT: 25 [21–30.5] vs. 26 [20–31]; P=0.519) , lower number of exacerbations in the previous half year [0 (0–1) vs. 1 (0–2); P=0.023], higher 6MWT values in the group with omega-3 supplementation	Higher BMI reduces the quality of life.
13.	Effects of the “Living well with COPD “ intervention in primary care [34]	2017	University of Zurich, Switzerland, University of Amsterdam, The Netherlands	prospectively planned, non-randomised controlled study	Age years: LWWCOPD group= 69.3±10.3 Control group= 67.1±10.0 Male: LWWCOPD= 28 (39.4%) Control= 225 (56.8%)	Inclusion criteria for both the mediX and ICE COLD ERIC cohorts were as follows: age ≥40 years; a smoking habit (current or past) ≥10 pack-years; a confirmed diagnosis of COPD; and a ratio (FEV1/FVC) ≤0.70, with less than 12% and less than 200 mL increases in	467 patients; 71 in the LWWCOPD self-management group and 396 in the ICE COLD ERIC routine care control group	Chronic Respiratory Questionnaire domain	LWWCOPD intervention improved HRQoL to a clinically relevant extent and reduced COPD exacerbations	Lack of patient counselling and self-management

Sr. No.	Study	Study year	University / Country	Study design	Mean age / Gender	Inclusion Criteria	Study population	Questionnaire used	QoL	QoL-Confounders
						FEV1, post dilatation, according to the GOLD & GOLD II-IV classifications . All participants be able to attend training sessions for 6 weeks.				
14.	The Effect of Pulmonary Rehabilitation in Mountain Environment on Exercise Capacity and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis [35]	2018	Department of Physical Medicine, Balneology and Medical Rehabilitation, Medical Faculty of P. J. Šafárik University and L. Pasteur University Hospital in Košice, Košice, Slovak Republic	Observational comparison	Age (years) COPD 65.7±11.9	Comparing 2 groups of patients (patients with COPD and patients with CB) before initiation of the treatment with baseline measurements, and again after the intervention of 3 weeks of pulmonary rehabilitation in a mountain environment.	128 consecutive patients (90 diagnosed with COPD and 38 diagnosed with CB)	QoL questionnaire SF-36	significant improvement after the intervention in all the monitored subscales and summative scores in both CB patients and COPD patients (p<0.001) for all.	insufficient use of rehabilitation options lack of research focused on mountain climate therapy
15.	Cross-sectional study evaluating the association between integrated care and health-related quality of life (HRQOL) in Dutch primary care [36]	2020.	Department of Health Services Research, Maastricht University, Maastricht, The Netherlands	Cross-sectional study	Mean age of the participants was 62.1 (14.4) years. 54.7% of the sample were female	The majority of the participants were married (70.3 %) and almost half (49 %) were retired. Of the participants, 449 were categorised in the high HRQOL group (58.3 %) and the remaining 321 were in the low HRQOL group (41.7%).	933 respondents participated	EQ-5D-3L	The present study showed that patients with a better organisational care coordination experience were more likely to have a higher HRQOL.	Unemployment and ageing were associated with lower HRQOL, and people who were married reported less anxiety and depression
16.	Results on health-related quality of life and functionality of a patient-centered selfmanagement program in hospitalized COPD: a randomized control trial [37]	2019	Department of Physiotherapy, University of Granada, Granada, Spain	Randomized clinical trial	Age (years): Control group=71.35±9.88 Physical therapy=71.20±11.53 Self-management group=72.63±7.37	Patients of both sexes were included as long as they were older than 40 years of age, were diagnosed with severe COPD according to the criteria of the GOLD 3 or 4), were hospitalized due to acute exacerbation of	a total of 66 patients were randomized in the three groups and performed the intervention with pre- and post-assessment.	The EQ-5D is a self-administered, health-related quality-of-life questionnaire	At 3 months, HRQoL shows reductions in all subscores in Control Group and Physical Therapy groups, while Self-Management group shows minimal maintenance of the values	cardiovascular disease, orthopedic diseases

Sr. No.	Study	Study year	University / Country	Study design	Mean age / Gender	Inclusion Criteria	Study population	Questionnaire used	QoL	QoL-Confounders
						COPD and agreed to participate.				
17.	Anemia Severely Reduces Health-Related Quality of Life in COPD Patients Receiving Long-Term Home Non-Invasive Ventilation [38]	2022	Witten/Herdecke University, Faculty of Health/School of Medicine, Germany	cohort study	Age [years]= 65.6 ± 8.1 Female/male [%] 46.1/53.9	Patients were only included if their chronic respiratory failure was primarily attributable to COPD. Regularly scheduled follow-up visits as well as those with acute problems	A total of 128 patients were enrolled for data analysis. Overall, 32.8% of the patients were anemic, while 4.7% had polycythemia	SRI	Overall, 32.8% of the patients were anemic, while 4.7% had polycythemia.	Anemia plays a highly important role in reducing HRQL in patients with chronic respiratory failure
18.	The Health Diary Telemonitoring and Hospital- Based Home Care Improve Quality of Life Among Elderly Multimorbid COPD and Chronic Heart Failure Subjects [39]	2022	Linköping, Linköping University, sweden.	cross-sectional study.	patients aged ≥65 years.	Elderly computer-illiterate subjects with ≥2 hospitalizations the previous year were included	94patients were enrolled of which 53 subjects completed the 12-month study period	St. Georges Respiratory Questionnaire (SGRQ)	the disease-specific HRQoL was worsened at the 12 month evaluation. At end-stage diseases subjects with COPD and CHF typically experience impaired functioning and impaired QoL.	Cardio vascular diseases, Smoking
19.	Chronic rhinosinusitis in COPD: A prevalent but unrecognized comorbidity impacting health related quality of life [40]	2020	Copenhagen University Hospital, Denmark	cross sectional study	Age, mean (SD)= 70.2 (8.9)	--	222 patients	CAT	CRS decreases HRQoL	asthma, bronchiectasis, cystic fibrosis and primary ciliary dyskinesia
20.	Can simvastatin reduce COPD exacerbations? A randomized double-blind controlled study [41]	2020	Medical University Vienna, Austria	randomized double-blind controlled study	Patients aged till 85 years/ Males	GOLD grade 2–4 were enrolled according to lung function criteria: ratio of forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) <70% and FEV1 <80% predicted after bronchodilator use. They were current or former smokers with ≥20 pack-years lifetime cigarette consumption.	208 patients	St George's Respiratory Questionnaire (SGRQ)	simvastatin at a dose of 40 mg daily significantly prolonged time to first COPD exacerbation and reduced exacerbation rate.	--

Sr. No.	Study	Study year	University / Country	Study design	Mean age / Gender	Inclusion Criteria	Study population	Questionnaire used	QoL	QoL-Confounders
21.	The quality of life in COPD patients in the process of physical rehabilitation [42]	2019	Nicolaus Copernicus University, Toruń, POLAND	randomized control trial (RCT)	Adult population. average age was 59.19 ± 0.74 years		124 patients. 64 (51.61%) males and 60 (48.39%) females	Ukrainian version of the World Health Organization Quality of Life Questionnaire (WHOQOL-100)	improvement of the overall quality of life increased indicators in problematic facets. decreased discomfort, decreased drug addiction, increased mobility, vital activity	--
22.	Predictive factors over time of health- related quality of life in COPD patients [43]	2020	Respiratory Department, Hospital Galdakao-Usansolo, Galdakao, Bizkaia, Spain	prospective observational longitudinal study	67years ±5 Males 308 Females 16	Patients were included in study if they diagnosed with COPD for at least 6months and had been stable for 6weeks. Other inclusion criteria were (FEV1) post-bronchodilator <80% of the predicted value and a FEV1/forced vital capacity ratio<70%	Geriatrics, 543 patients at start. Over 5year 324 left.	Saint George's Respiratory Questionnaire (SGRQ),	PA was related to a 13 to 35% better activity and impacts scores of HRQoL, depending on the level of PA, hospitalizations were related to 5 to 45% poorer HRQoL scores. Pulmonary function was associated with all HRQoL components, with an approximately 5% improvement in HRQoL	Reduced physical activity and hospitalizations for exacerbation.

Results of quality of life: Out of 22 studies, nine studies showed the reduced quality of life due to various factors.

Remaining studies showed the improvement in quality of life due to hospital admissions, increased physical activities, and use of drugs for exacerbation reduction, better organisational care, LWWCOPD intervention, supplementation and weight reduction.

Factors that causes reduction of quality of life: Out of 22 studies, four studies discussed comorbidities as a factor of reduced quality of life along with COPD. Major diseases reported are Diabetes Mellitus, Cardiovascular diseases, Arterial hypertension, asthma, cystic fibrosis, orthopaedic diseases.

Smoking has been a prime factor of reducing the quality of life in COPD patients. Three studies majorly highlighted smoking and tobacco as a factor. Malnutrition and low HDL has also been discussed with this.

Two studies explains psychiatric issues like depression and anxiety as a factor that reduces quality of life in COPD patients. Also reported that people who are married are reported with other factors majorly instead of depression and anxiety in reduced QoL.

One study from Denmark explained cancer of lung, neck and head as a factor of reduced quality of life in COPD patients.

One of the study has discussed obesity as a factor that plays a part in reducing quality of life.

Anemia has also been discussed as the reason in one study picked from Germany along with chronic respiratory failure in reducing the QoL of COPD patients.

Three studies described high degree of symptoms i.e. sever exacerbation, decreased physical activities, unemployment, ageing as a main factors in reducing or decreasing the quality of life.

According to one study from Hungary, says high body mass index (BMI), less walk also leads to the same condition. Two studies from Spain described age, gender, traffic related air pollutants (NO₂, PM₂), residential distances to blue green spaces and pseudomonas aeruginosa for the severity of COPD and reduction of quality of life.

Lack of counselling and self-management has also been the reason for decreased QoL in one study.

One study collected from Sovak Republic says insufficient use of rehabilitations options and lack of research focused on mountain climate therapy are the factors.

Two studies didn't mention factors that causes the reduction of QoL. And one study described that hospitalization for exacerbations and physical activities can influence the health related quality of life.

4. DISCUSSION

The state of health in individuals with COPD is impacted by numerous variables. However, because there are numerous questionnaires in use and some factors affect multiple sections or domains of the existing questionnaires, it is challenging to assess the degree of influence of each factor on health status. Several studies have also been conducted on evaluation of quality of life among COPD patients. This review evaluates the quality of life among COPD patients in European union countries and the effects of variable factors and different interventions on the quality of life.

This review presents that smoking is a prime factor of reducing the quality of life in COPD patients .Three studies majorly highlighted that smoking and tobacco as a cofactor .Similar results were shown by study conducted in chest disease research institute Kyoto ,Japan on 132 patients using Nottingham Health Profile as a general HRQL measure that reported air flow limitation, diffusing capacity ,life time cigarette consumption were significant predicators of HRQL in stable COPD patients.[44] In contrast a review article having databases from 2006 to 2007 from different countries of world by N.S.Godtfredson suggested that smoking cessation recommendation is not proportionate to degree of morbidity cause by smoking. . "Smoking cessation in mild-to-moderate disease can prevent progression of disease severity; however, it is not known what characterizes smokers with different stages of COPD who choose to stop smoking compared with those who continue". (Godtfredsen, Lam et al. 2008)

This systemic review provides insight into the association of comorbidities and reduced quality of life in COPD patients .out of 22 studies four studies discussed comorbidities like Diabetes

mellitus, cardiovascular disease, arterial hypertension, asthma, cystic fibrosis and orthopedic disease as factor of reduced quality of life. Similar results were shown in a systematic review by Manuel B.Huber, who concluded results from 25 studies of different parts of world ,in which it was clearly shown that certain comorbidities like CVD and diabetes worsen the quality of life in COPD patients.[27] “In contrast a cross sectional study conducted in 2002 in Netherland institute for health services research among 161 COPD patients and 395 asthma patients recruited from general practice reported that cardiac disease is associated with HRQoL in asthma but not in COPD. The presence of hypertension is not associated with poor disease specific HRQoL in COPD patients” [45].

“The data from the studies also showed that the psychiatric issues like depression and anxiety are also the major factors that reduce the quality of life in COPD patients. Similar results were shown in a cross section analysis of data from the French COPD cohort initiatives BPCO ,data recorded in stable state and included spirometry ,dyspnea, mood disorders and comorbidities . The data suggested that in presence of dyspnea and exacerbations ,depression is the most important contributor to HRQoL impairment measured by SGRQ in COPD patients”. [18] “In contrast a systematic review by Amy Baranaik in 2009 data collected from electronic journals and databases suggested that efficacy of psychological interventions to improve anxiety, depression and quality of life in COPD patients is relatively sparse”.[18]

Anemia has also been discussed as the reason in one study picked from Germany along with chronic respiratory failure in reducing the QoL of COPD patients .similar evidence shown in a retrospective study conducted by Marcello in Italy in which previous record of 105 patients analyzed .the study suggested that prevalence of anemia is 12.3% in COPD patients .anemia associated with reduction of exercise capacity, an increase of dyspnea and deterioration of quality of life. [46] In contrast a study conducted by Casanova et al in hospital Universitario Quiron Madrid on 130 COPD patients suggested that anemia prevalence was only 6.2% in patients ,it was less prevalent [47].

The data from the studies in this review also depicted an association between nutritional status and the quality of life in COPD patients. Malnutrition increases dyspnea and exercise intolerance in COPD patients. BMI is closely

related to dyspnea. Similarly , a prospective study conducted in department of chest diseases in Istanbul Turkey by Banu et al on 65 COPD patients also suggested that malnutrition is linked to a marked decrease in the strength and endurance of the respiratory muscles, an increase in airflow restriction, and an exacerbation of respiratory muscle dysfunction already present caused by hyperinflation. [48]. In contrast a prospective randomized controlled trial study conducted by Efthimiou et al in UK to investigate the effect of 3 months of oral supplementation in 14 poorly nourished outpatients with COPD reported that following three months of nutritional supplements, there were no differences in the pulmonary functions of moderate-to-severe COPD patients who were undernourished compared to those who were well-nourished [49].

The data from the study also showed that the cancer of head, neck and lung also contribute to reduce the quality of life. This finding is similar to the retrospective study conducted in South Korea by Young soo-yi which reported that high prevalence of COPD was found in patients with non-small cell lung cancer with diminished quality of life [13].

The data from the studies also suggest association between obesity and reduced health related quality of life in COPD patients. Similar results were shown by the cohort study conducted on 364 patients in Washington by Laura et al in which obese patients reported increased severity of dyspnea and overall poor health related quality of life [50]. In contrast a cohort study conducted in France by Pierre on 633 patients reported that in presence of dyspnea ,depression was the most important factor in reducing quality of life while obesity has little effect in reducing quality of life [18].

This review also depicted an important factor traffic related air pollutant in reducing the quality of life in COPD patients .Similarly a cross sectional study conducted in Hong kong by Fong et al also described a strong association between the quality of air and the reduced quality of life in COPD patients [51].

In same way a cross sectional study on 407 stable COPD patients conducted in Spain by Moitra et al also showed that high residential exposure to traffic related air pollutants are associated with poorer quality of life in COPD patients [31].

The study included in this review suggested that insufficient use of rehabilitation facilities has great impact in reducing the quality of life in COPD patients. Similarly a systematic review in Germany by Micheal et al interpreted that non pharmacological interventions like pulmonary rehabilitation and counseling has important role in improving the quality of life in COPD patients [52,53,54].

5. CONCLUSION

All the studies concluded that COPD patients diagnosed on basis of GOLD criteria and their quality of life is assessed via disease specific questionnaires that majorly includes SGRQ, CAT, CCQ, EQ-5D-5L. The study designs we included were observational, cross sectional, randomized, experimental and cohort. Overall, decrease in quality of life in patients of COPD has been seen and observed. Factors that contribute in this are comorbidities (cardiovascular diseases, arterial hypertension, psychotic disorders, diabetes mellitus, orthopedic diseases), obesity, traffic irritants, pollutants, anemia. Also one study claims lung, head and neck cancer to contribute in the reduction of quality of life in COPD patients. This compromised life of COPD patients then leads to less physical activities, high BMI, less walking. Proper hospitalization and follow up can make the health a little better but cannot save a person from mortality.

6. LIMITATIONS OF THE STUDY

The current study is a systematic review of QoL of COPD patients from the regions of Europe. Therefore, it lacks the worldwide prospective.

CONSENT

It is not applicable.

ETHICAL APPROVAL

The current systematic review was conducted after getting ethical approval from the university's ethical review board with ethical protocol number: ERB-PHRMD-DPP/4529-A.

ACKNOWLEDGEMENT

We thank Department of Pharmacy Practice, Faculty of Pharmaceutical Science, Lahore University of Biological and Applied Sciences for their kind contribution and guidance in the preparation of this research work.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Spurzem JR, Rennard SI. Pathogenesis of COPD. In seminars in respiratory and critical care medicine 2005 Apr;26(02):142-153). Published by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. DOI: 10.1055/s-2005-869535
2. Weldam SW, Schuurmans MJ, Liu R, Lammers JW. Evaluation of quality of life instruments for use in COPD care and research: A systematic review. International journal of nursing studies. 2013 May 1;50(5):688-707. Available:https://doi.org/10.1016/j.ijnurstu.2012.07.017
3. Cave AJ, Atkinson L, Tsiligianni IG, Kaplan AG. Assessment of COPD wellness tools for use in primary care: an IPCRG initiative. International Journal of Chronic Obstructive Pulmonary Disease. 2012 Jul 17:447-56. Available:http://dx.doi.org/10.2147/COPD.S29868
4. Almagro P, Castro A. Helping COPD patients change health behavior in order to improve their quality of life. International Journal of Chronic Obstructive Pulmonary Disease. 2013 Jul 24:335-45. Available:https://doi.org/10.2147/COPD.S34211
5. Barnes PJ. Mechanisms in COPD: Differences from asthma. Chest. 2000 Feb 1;117(2):10S-4S. Available:https://doi.org/10.1378/chest.117.2_suppl.10S
6. Cukic V, Lovre V, Dragisic D, Ustamujic A. Asthma and chronic obstructive pulmonary disease (COPD)—differences and similarities. *Materia Socio-Medica*. 2012; 24(2):100. Available:https://doi.org/10.5455%2Fmsm.2012.24.100-105
7. Gibson PG, McDonald VM. Asthma–COPD overlap 2015: now we are six. *Thorax*. 2015 Jul 1;70(7):683-91. DOI: 10.1183/09031936.00160007
8. Hynninen MJ, Pallesen S, Nordhus IH. Factors affecting health status in COPD patients with co-morbid anxiety or depression. *International Journal of*

- Chronic Obstructive Pulmonary Disease. 2007 Jan 1;2(3):323-8.
9. Eisner MD, Blanc PD, Yelin EH, Katz PP, Sanchez G, Iribarren C, Omachi TA. Influence of anxiety on health outcomes in COPD. *Thorax*. 2010 Mar 1;65(3):229-34. Available: <https://doi.org/10.1136/thx.2009.126201>
 10. Jarab A, Alefishat E, Mukattash T, Alzoubi K, Pinto S. Patients' perspective of the impact of COPD on quality of life: A focus group study for patients with COPD. *International Journal of Clinical Pharmacy*. 2018 Jun;40:573-9. Available: <https://doi.org/10.1007/s11096-018-0614-z>
 11. Wouters EF, Creutzberg EC, Schols AM. Systemic effects in COPD. *Chest*. 2002 May 1;121(5):127S-30S. Available: https://doi.org/10.1378/chest.121.5_suppl.127S
 12. Decramer M, De Benedetto F, Del Ponte A, Marinari S. Systemic effects of COPD. *Respiratory Medicine*. 2005 Dec 1;99:S3-10. Available: <https://doi.org/10.1016/j.rmed.2005.09.010>
 13. Yi YS, Ban WH, Sohng KY. Effect of COPD on symptoms, quality of life and prognosis in patients with advanced non-small cell lung cancer. *BMC Cancer*. 2018 Dec;18(1):1-8. Available: <https://doi.org/10.1186/s12885-018-4976-3>
 14. Roche N. Stable COPD treatment: Where are we?. *COPD: Journal of Chronic Obstructive Pulmonary Disease*. 2018 Mar 4;15(2):123-9. Available: <https://doi.org/10.1080/15412555.2018.1445214>
 15. Fromer L. Diagnosing and treating COPD: understanding the challenges and finding solutions. *International Journal of General Medicine*. 2011 Oct 28;729-39. Available: <http://dx.doi.org/10.2147/IJGM.S21387>
 16. Tsiligianni I, Kocks J, Tzanakis N, Siafakas N, van der Molen T. Factors that influence disease-specific quality of life or health status in patients with COPD: a review and meta-analysis of Pearson correlations. *Primary Care Respiratory Journal: Journal of the General Practice Airways Group*. 2011 Sep 1;20(3):257-68. Available: <https://doi.org/10.4104/pcrj.2011.00029>
 17. Wacker ME, Jörres RA, Karch A, Wilke S, Heinrich J, Karrasch S, Koch A, Schulz H, Watz H, Leidl R, Vogelmeier C. Assessing health-related quality of life in COPD: Comparing generic and disease-specific instruments with focus on comorbidities. *BMC pulmonary medicine*. 2016 Dec;16:1-1. Available: <https://doi.org/10.1186/s12890-016-0238-9>
 18. Burgel PR, Escamilla R, Perez T, Carré P, Caillaud D, Chanez P, Pinet C, Jebrak G, Brinchault G, Court-Fortune I, Paillasseur JL. Impact of comorbidities on COPD-specific health-related quality of life. *Respiratory Medicine*. 2013 Feb 1;107(2):233-41. Available: <https://doi.org/10.1016/j.rmed.2012.10.002>
 19. Flokstra-de Blok BM, DunnGalvin A, Vlieg-Boerstra BJ, Elberink JN, Duiverman EJ, Hourihane JO, Dubois AE. Development and validation of the self-administered Food Allergy Quality of Life Questionnaire for adolescents. *Journal of Allergy and Clinical Immunology*. 2008 Jul 1;122(1):139-44. Available: <https://doi.org/10.1016/j.jaci.2008.05.008>
 20. Windisch W. Impact of home mechanical ventilation on health-related quality of life. *European Respiratory Journal*. 2008 Nov 1;32(5):1328-36. DOI: 10.1183/09031936.00066407
 21. Menn P, Weber N, Holle R. Health-related quality of life in patients with severe COPD hospitalized for exacerbations-comparing EQ-5D, SF-12 and SGRQ. *Health and Quality of Life Outcomes*. 2010 Dec;8(1):1-9. Available: <https://doi.org/10.1186/1477-7525-8-39>
 22. Duiverman ML, Wempe JB, Bladder G, Kerstjens HA, Wijkstra PJ. Health-related quality of life in COPD patients with chronic respiratory failure. *European Respiratory Journal*. 2008 Aug 1;32(2):379-86. DOI: 10.1183/09031936.00163607
 23. Horner A, Burghuber OC, Hartl S, Studnicka M, Merkle M, Olschewski H, Kaiser B, Wallner EM, Lamprecht B. Quality of life and limitations in daily life of stable COPD outpatients in a real-world setting in Austria—results from the CLARA Project. *International journal of chronic obstructive pulmonary disease*. 2020 Jul 12:1655-63. Available: <http://doi.org/10.2147/COPD.S252033>

24. Mekov E, Petkov R, Tsakova A, Genova M, Kostadinov D. Two-Year Mortality Following a Severe COPD Exacerbation in Bulgarian Patients. *Acta Medica Bulgarica*. 2022;49(2):33-8.
Available:<https://doi.org/10.2478/amb-2022-0017>
25. Tupper OD, Gregersen TL, Ringbaek T, Brøndum E, Frausing E, Green A, Ulrik CS. Effect of tele-health care on quality of life in patients with severe COPD: A randomized clinical trial. *International Journal of Chronic Obstructive Pulmonary Disease*. 2018 Aug 29;2657-62.
Available:<https://www.tandfonline.com/doi/full/10.2147/COPD.S164121>
26. Brandl M, Böhmer MM, Brandstetter S, Finger T, Fischer W, Pfeifer M, Apfelbacher C. Factors associated with generic health-related quality of life (HRQOL) in patients with chronic obstructive pulmonary disease (COPD): A cross-sectional study. *Journal of Thoracic Disease*. 2018 Feb;10(2):766.
Available:<https://doi.org/10.21037%2Fjtd.2018.01.122>
27. Huber MB, Kurz C, Kirsch F, Schwarzkopf L, Schramm A, Leidl R. The relationship between body mass index and health-related quality of life in COPD: real-world evidence based on claims and survey data. *Respiratory Research*. 2020 Dec;21(1):1-0.
Available:<https://doi.org/10.1186/s12931-020-01556-0>
28. Gottlieb M, Mellempgaard A, Marsaa K, Godtfredsen N. Optimizing COPD treatment in patients with lung-or head and neck cancer does not improve quality of life—a randomized, pilot, clinical trial. *European Clinical Respiratory Journal*. 2020 Jan 1;7(1):1731277.
Available:<https://doi.org/10.1080/20018525.2020.1731277>
29. Stöber A, Lutter JI, Schwarzkopf L, Kirsch F, Schramm A, Vogelmeier CF, Leidl R. Impact of lung function and exacerbations on health-related quality of life in COPD patients within one year: real-world analysis based on claims data. *International Journal of Chronic Obstructive Pulmonary Disease*. 2021 Sep 21;2637-51.
Available:<https://doi.org/10.1080/14737167.2019.1662302>
30. Cosío BG, Shafiek H, Verdú J, Fiorentino F, Valera JL, Martínez R, Romero S, Ramón L, Toledo-Pons N, Sala E. Implementation of an integrated care model for frequent-exacerbator COPD patients: a controlled prospective study. *Archivos de Bronconeumologia*. 2021 Sep 1;57(9):577-83.
Available:<https://doi.org/10.1016/j.arbres.2021.01.025>
31. Moitra S, Foraster M, Arbillaga-Etxarri A, Marín A, Barberan-Garcia A, Rodríguez-Chiaradia DA, Balcells E, Koreny M, Torán-Monserrat P, Vall-Casas P, Rodríguez-Roisin R. Roles of the physical environment in health-related quality of life in patients with chronic obstructive pulmonary disease. *Environmental Research*. 2022 Jan 1;203:111828.
Available:<https://doi.org/10.1016/j.envres.2021.111828>
32. Folch-Ayora A, Orts-Cortés MI, Macia-Soler L, Andreu-Guillamon MV, Moncho J. Patient education during hospital admission due to exacerbation of chronic obstructive pulmonary disease: Effects on quality of life—Controlled and randomized experimental study. *Patient Education and Counseling*. 2019 Mar 1;102(3):511-9.
Available:<https://doi.org/10.1016/j.pec.2018.09.013>
33. Fekete M, Szarvas Z, Fazekas-Pongor V, Lehoczki A, Tarantini S, Varga JT. Effects of omega-3 supplementation on quality of life, nutritional status, inflammatory parameters, lipid profile, exercise tolerance and inhaled medications in chronic obstructive pulmonary disease. *Ann. Palliat. Med*. 2022 Sep 1;11:2819-29.
34. Steurer-Stey C, Dalla Lana K, Braun J, Ter Riet G, Puhan MA. Effects of the “Living well with COPD” intervention in primary care: A comparative study. *European Respiratory Journal*. 2018 Jan 1; 51(1).
DOI: 10.1183/13993003.01375-2017
35. Kubincová A, Takáč P, Kendrová L, Joppa P, Mikuláková W. The effect of pulmonary rehabilitation in mountain environment on exercise capacity and quality of life in patients with chronic obstructive pulmonary disease (COPD) and chronic bronchitis. *Medical Science Monitor: International Medical Journal of Experimental and Clinical Research*. 2018;24:6375.
Available:<https://doi.org/10.12659%2FMS.M.909777>
36. Valentijn PP, Kerkhoven M, Heideman J, Arends R. Cross-sectional study evaluating the association between integrated care and health-related quality of life (HRQOL)

- in Dutch primary care. *BMJ Open*. 2021 Apr 1;11(4):e040781. Available:<https://doi.org/10.1136/bmjopen-2020-040781>
37. Lopez-Lopez L, Valenza MC, Rodriguez-Torres J, Torres-Sanchez I, Granados-Santiago M, Valenza-Demet G. Results on health-related quality of life and functionality of a patient-centered self-management program in hospitalized COPD: A randomized control trial. *Disability and Rehabilitation*. 2020 Dec 3;42(25):3687-95. Available:<https://doi.org/10.1080/09638288.2019.1609099>
 38. Wollsching-Strobel M, Schwarz SB, Mathes T, Majorski DS, Heidari P, Kroppen D, Magnet FS, Windisch W. Anemia severely reduces health-related quality of life in COPD patients receiving long-term home non-invasive ventilation. *International Journal of Chronic Obstructive Pulmonary Disease*. 2021 Oct 28:2963-71. Available:<https://www.tandfonline.com/doi/full/10.2147/COPD.S328404>
 39. Persson HL, Lyth J, Lind L. The health diary telemonitoring and hospital-based home care improve quality of life among elderly multimorbid COPD and chronic heart failure subjects. *International Journal of Chronic Obstructive Pulmonary Disease*. 2020 Mar 9:527-41. Available:<http://doi.org/10.2147/COPD.S236192>
 40. Arndal E, Sørensen AL, Lapperre TS, Said N, Trampedach C, Aanæs K, Alanin MC, Christensen KB, Backer V, von Buchwald C. Chronic rhinosinusitis in COPD: A prevalent but unrecognized comorbidity impacting health related quality of life. *Respiratory Medicine*. 2020 Sep 1;171:106092. Available:<https://doi.org/10.1016/j.rmed.2020.106092>
 41. Schenk P, et al. Can simvastatin reduce COPD exacerbations? A randomised double-blind controlled study. *European Respiratory Journal*. 2021; 58(1). DOI: 10.1183/13993003.01798-2020
 42. Grygus I, Nesterchuk N, Zukow W, Nikolenko O, Prymachok L. The quality of life in COPD patients in the process of physical rehabilitation. *Journal of Physical Education and Sport*. 2019 Jun 1;19(2): 1126-32. DOI:10.7752/jpes.2019.02163
 43. Esteban C, Arostegui I, Aramburu A, Moraza J, Najera-Zuloaga J, Aburto M, Aizpiri S, Chasco L, Quintana JM. Predictive factors over time of health-related quality of life in COPD patients. *Respiratory Research*. 2020 Dec;21:1-1. Available:<https://doi.org/10.1186/s12931-020-01395-z>
 44. Tsukino M, Nishimura K, Ikeda A, Koyama H, Mishima M, Izumi T. Physiologic factors that determine the health-related quality of life in patients with COPD. *Chest*. 1996 Oct 1;110(4):896-903. Available:<https://doi.org/10.1378/chest.110.4.896>
 45. Wijnhoven HA, Kriegsman DM, Hesselink AE, De Haan M, Schellevis FG. The influence of co-morbidity on health-related quality of life in asthma and COPD patients. *Respiratory Medicine*. 2003 May 1;97(5):468-75. Available:<https://doi.org/10.1053/rmed.2002.1463>
 46. Ferrari M, Manea L, Anton K, Bruzzone P, Meneghello M, Zamboni F, Purgato L, Cazzoletti L, Ferrari P, Testi R. Anemia and hemoglobin serum levels are associated with exercise capacity and quality of life in chronic obstructive pulmonary disease. *BMC pulmonary medicine*. 2015 Dec;15(1):1-8. Available:<https://doi.org/10.1186/s12890-015-0050-y>
 47. Casanova LC, Echave-Sustaeta JM, Luján RG, Lozano IA, González PA, Alonso MJ. Prevalence of anaemia associated with chronic obstructive pulmonary disease. Study of associated variables. *Archivos de Bronconeumología (English Edition)*. 2013 Sep 1;49(9):383-7. Available:<https://doi.org/10.1016/j.arbr.2013.07.010>
 48. Salepci B, Eren A, Cağlayan B, Fidan A, Torun E, Kiral N. The effect of body mass index on functional parameters and quality of life in COPD patients. *Tuberk Toraks*. 2007 Jan 1;55(4):342-9.
 49. Efthimiou J, Fleming J, Gomes C, Spiro SG. The effect of supplementary oral nutrition in poorly nourished patients with chronic obstructive pulmonary disease. *Am Rev Respir Dis*. 1988 May 1;137(5):1075-82. Available:<https://doi.org/10.1164/ajrccm/137.5.1075>
 50. Cecere LM, Littman AJ, Slatore CG, Udris EM, Bryson CL, Boyko EJ, Pierson DJ, Au DH. Obesity and COPD: associated

- symptoms, health-related quality of life, and medication use. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2011 Aug 18;8(4):275-84.
Available:<https://doi.org/10.3109/15412555.2011.586660>
51. Fong KN, Mui KW, Chan WY, Wong LT. Air quality influence on chronic obstructive pulmonary disease (COPD) patients' quality of life. Indoor Air. 2010 Oct;20(5):434-41.
Available:<https://doi.org/10.1111/j.1600-0668.2010.00668.x>
52. Hindelang M, Kirsch F, Leidl R. Effectiveness of non-pharmacological COPD management on health-related quality of life-a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research. 2020 Jan 2;20(1):79-91.
Available:<https://doi.org/10.1080/14737167.2020.1734455>
53. Esteban C, Quintana JM, Aburto M, Moraza J, Egurrola M, Pérez-Izquierdo J, Aizpiri S, Aguirre U, Capelastegui A. Impact of changes in physical activity on health-related quality of life among patients with COPD. European Respiratory Journal. 2010 Aug 1;36(2):292-300.
DOI: 10.1183/09031936.00021409
54. Laxy M, Teuner C, Holle R, Kurz C. The association between BMI and health-related quality of life in the US population: Sex, age and ethnicity matters. International Journal of Obesity. 2018 Mar;42(3):318-26.
Available:<https://doi.org/10.1038/ijo.2017.252>

© Copyright (2024): Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
<https://www.sdiarticle5.com/review-history/114123>